MK-677 (Ibutamoren) Dosage Guide: Protocols, Calculator & Safety

Goal: establish tolerance at a conservative dose before committing to the full 25 mg/day protocol.

Low-dose MK-677 — weeks 1-4

• Dose: 10 mg orally, once daily
• Timing: Pre-bed, on an empty stomach (≥2 hours after last meal)
• Why pre-bed: The 24-hour half-life means timing is less critical than for injectable GHS, but pre-bed dosing (a) maximizes sleep-architecture benefit, (b) reduces perceived appetite effect during waking hours, and (c) aligns with the nocturnal GH burst
• Why 10 mg vs 25 mg: At 10 mg, IGF-1 typically rises ~40-50% with substantially less water retention, appetite stimulation, and glucose effect than the 25 mg dose. For many users 10 mg provides 70-80% of the benefit with 30% of the side-effect burden

Form factors

• Capsules — most common; 10 mg capsule or split 25 mg capsule
• Oral liquid — faster absorption, easier dose adjustment; typical concentration 25 mg/mL
• Sublingual / dissolvable tablet — marginal bioavailability advantage; negligible vs swallowed capsule

What to expect in weeks 1-4

• Week 1: vivid dreams, evening hunger, mild water retention (~1 kg scale weight)
• Week 2-3: improved recovery and sleep quality; hunger stabilizes
• Week 4: IGF-1 rising toward steady state; subjective benefits consolidating

Required monitoring for beginners

• Baseline: IGF-1, fasting glucose, HbA1c, CBC, CMP, lipid panel, PSA (men >40), thyroid
• Week 4: IGF-1, fasting glucose
• Scale weight daily — to track fluid retention trend

When NOT to proceed to intermediate

• Fasting glucose rise >10 mg/dL from baseline → hold dose escalation
• Scale weight up >2 kg with persistent edema → hold or reduce
• Any carpal tunnel symptoms → hold or reduce
• No subjective benefit at week 4 on 10 mg → consider the underlying question of whether MK-677 is the right tool vs injectable GHS

At week 4, reassess. If tolerance is good and effect is modest, progress to 20-25 mg/day. If 10 mg is producing the desired effects, many users stay there indefinitely — there is no mandatory escalation.

Goal: the standard 25 mg/day MK-677 protocol, as used in the Nass 2008 trial and the reference biohacking protocol.

Standard MK-677 — weeks 1-12 (or continuous within cycle)

• Dose: 25 mg orally, once daily
• Timing: Pre-bed, empty stomach preferred (≥2 hours post-meal)
• Cycle length: 8-16 weeks on / 4-6 weeks off is the conservative approach; the Nass trial ran 2 years continuous with good tolerance in most patients

Why 25 mg specifically

• Established dose from Murphy 1998 PK and Chapman 1996 dose-response — above 25 mg the IGF-1 dose-response plateaus while side effects continue to scale
• Validated in the longest human trial (Nass 2008, 2 years)
• Balance point between effect size and side-effect burden

Timing nuances

• Pre-bed empty stomach: standard; maximizes sleep benefit
• Morning fasted: alternative for users whose evening hunger is too disruptive; does not reduce efficacy significantly because of the 24h half-life
• With food: reduces absorption mildly (~15%); most users can take MK-677 with food if empty stomach is not practical

Stacking at this tier

MK-677 can be stacked with but does not typically combine with injectable GHS peptides (redundant at the receptor — see stacking notes). Common co-interventions:

• Testosterone or TRT — complementary hormone axes
• Semaglutide / Tirzepatide — MK-677 can counteract the GLP-1-induced appetite suppression if lean mass preservation is the goal (the appetite dimension runs in opposite directions — be deliberate about which you want to win)
• BPC-157 + TB-500 — connective tissue repair synergy with GH/IGF-1 elevation
• Metformin 500-1000 mg/day — off-label; counters the MK-677-induced insulin resistance; commonly stacked in bodybuilding protocols

Bloodwork

• Baseline: IGF-1, fasting glucose, HbA1c, insulin, CBC, CMP, lipid panel, PSA (men >40), thyroid, estradiol
• Week 4: IGF-1, fasting glucose, insulin
• Week 8: Full panel
• End of cycle: Full panel + reassess
• Scale weight and waist measurement weekly

When to dose-reduce or stop

• IGF-1 >300 ng/mL (supraphysiologic) → reduce to 15 mg or cycle off
• HbA1c rising >0.3 points → counter with metformin or cycle off
• Persistent edema, carpal tunnel, or new cardiac symptoms → stop and reassess
• Any chest pain, dyspnea, or CHF-like symptoms (rare but documented) → stop immediately and seek medical evaluation

Goal: optimize MK-677 effects within the physiologic envelope while managing its characteristic side-effect profile. For experienced users with full lab monitoring.

Pulsed 25 mg protocol with insulin-sensitizer co-therapy — 12-24 weeks

For users pursuing extended MK-677 use with managed side effects:

• MK-677: 25 mg orally pre-bed
• Metformin: 500-1000 mg/day (off-label insulin-sensitizer)
• Optional addition: Enclomiphene 12.5-25 mg/day if TRT-like effects without exogenous testosterone are desired

Rationale: Metformin directly addresses MK-677's primary durable side effect (glucose intolerance) while preserving the GH/IGF-1 benefits. This is not Merck-tested; it is extrapolation from known metformin pharmacology and routine bodybuilding practice.

High-dose protocol — NOT RECOMMENDED

Some bodybuilding protocols use 50 mg or higher MK-677. The data is clear:

• Chapman 1996 showed dose-response plateaus above 25 mg for IGF-1
• Side effects continue to scale linearly: more water retention, more hunger, more glucose effect
• No evidence of clinically meaningful incremental benefit
• Do not exceed 25 mg/day

Split-dose protocol — alternative for hunger management

For users whose evening hunger is intolerable:

• 12.5 mg AM (morning fasted) + 12.5 mg pre-bed
• 24h half-life means this is pharmacokinetically similar to once-daily dosing
• Splits the appetite signal across the day rather than concentrating it in the evening

Cycling strategies

• Standard: 12 weeks on / 4-6 weeks off
• Long cycle: 24 weeks on / 8 weeks off (the Nass-trial-reference approach)
• Continuous: validated in Nass 2008 for 2 years; not generally recommended for healthy biohackers pursuing longevity protocols due to long-term safety uncertainty

Body recomposition with GLP-1 therapy

MK-677 + semaglutide / tirzepatide is the recomposition stack for users who want:

• GLP-1-driven fat loss
• GH/IGF-1 lean mass preservation
• Appetite management — GLP-1 suppresses appetite more than MK-677 stimulates it at clinical doses, so the net is still hypocaloric but less aggressively than GLP-1 alone

Contraindications specific to advanced dosing

• Any history of CHF or NYHA II-IV — absolute (Nass trial CHF signal)
• Uncontrolled T2DM — use with extreme caution and endocrinology supervision
• Active malignancy — absolute
• Diabetic retinopathy — relative contraindication
• History of acromegaly or pituitary adenoma — absolute